Some of functionality may not work while you disabled JavaScript. Enable JavaScript for better User Exprience. September 23, 2020

Rediscovery Life Sciences Completes $4.5M Series B Financing

RALEIGH, N.C., September 23, 2020-- Rediscovery Life Sciences, LLC (RLS), a clinical-stage biotechnology company, announced the closing of its most recent financing. The Series B financing was co-led by REX Health Ventures (the investment arm of UNC REX Healthcare) and Orlando Health Ventures. RLS will use the proceeds to fund a Phase 2 trial of suramin in diuretic resistant Acute Kidney Injury (AKI). Anita Watkins, JD, Director of REX Health Ventures, and Dr. Sunil Desai, President of the Orlando Health Medical Group, have joined RLS's Board of Directors.
Read by 46% of LPs August 04, 2020

Healthcare & Life Sciences Private Equity Deal Tracker: Ta Associates And Francisco Partners Invest In Edifecs | Mcguirewoods Llp

TA Associates and Francisco Partners have signed a definitive agreement to make a significant growth investment in Edifecs, according to a news release....By: McGuireWoods LLP.
Read by 65% of LPs July 20, 2020

Healthcare & Life Sciences Private Equity Deal Tracker: Ew Healthcare Partners Leads Investment In Cardiva Medical | Mcguirewoods Llp

EW Healthcare Partners has led a $45 million equity financing round into Cardiva Medical, according to a news release....By: McGuireWoods LLP.
Read by 31% of LPs July 17, 2020

Healthcare & Life Sciences Private Equity Deal Tracker: Accel-kkr Invests In Forcura | Mcguirewoods Llp

Accel-KKR has made a "significant" growth investment in healthcare technology company Forcura, according to a news release....By: McGuireWoods LLP. : Accel-KKR has made a "significant" growth investment in healthcare technology company Forcura, according to a news release. Forcura, based in Jacksonville, Fla., is a developer of document management and communication solutions for home health and hospice organizations. Accel-KKR, based in Menlo Park, Calif., is a technology-focused investment firm. The firm pursues middle-market companies and provides a broad range of capital solutions, including buyout capital, minority-growth investments and credit alternatives.
Read by 43% of LPs June 22, 2020

Innovatus Appoints Geoffrey Duyk, M.d., Ph.d. To Its Life Sciences Advisory Board

NEW YORK--(BUSINESS WIRE)--Innovatus Capital Partners, LLC ("Innovatus" or the "Firm"), an independent adviser and portfolio management firm with approximately $1.6 billion in assets under management, today announced that it has appointed Geoffrey Duyk, M.D., Ph.D., the founder and Managing Partner of Circularis LP, to its Life Sciences Advisory Board. Headquartered in New York, Innovatus Capital Partners' Life Sciences strategy ("Innovatus Life Sciences") provides growth capital in the form of.
Read by 56% of LPs May 28, 2020

Orbita Raises $9M To Accelerate Conversational Ai Solutions In Healthcare And Life Sciences

Round co-led by Philips Health Technology Ventures and HealthX Ventures along with investors Cultivation Capital and Newark Venture Partners BOSTON, May 28, 2020-- Orbita, the leading provider of conversational AI-powered voice and chatbot solutions for healthcare, announced today that it has secured $9M of venture funding as part of the company's Series A financing round. Co-leading the round are Philips Health Technology Ventures, which manages a business-agnostic fund investing in future partners to drive Philips' digital transformation, and HealthX Ventures, a digital healthcare-focused venture capital firm. Cultivation Capital and Newark Venture Partners also participated in the round.
Read by 54% of LPs May 22, 2020

Calcimedica Raises $15M In Series C Financing Round Led By Valence Life Sciences

Funds to support ongoing clinical trials in patients with COVID-19 pneumonia and commercial manufacturing of Auxora(tm) LA JOLLA, Calif., May 22, 2020-- CalciMedica Inc. ("CalciMedica" or the "Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment of acute and severe inflammatory diseases, today announced it has raised $15 million in a Series C financing round. The round was led by Valence Life Sciences, LLC with participation from new investors Bering Capital, Mesa Verde Venture Partners and existing investor Sanderling Ventures.
Read by 41% of LPs May 21, 2020

Calico Life Sciences Founder Says He's 'disappointed' With Progress

Bill Maris, who founded Google Ventures and left to build his own investment fund called Section 32, just brought aboard several former Googlers to his new company. Among those is Claire Stapleton, a previous YouTube executive who led an employee walkout at Google in 2018 to protest the company's handling of sexual-misconduct allegations. Maris also founded Calico, the secretive life-sciences company that still sits under Alphabet. He said he's "disappointed" with the lack of progress Calico has shown since his departure. Click here to get BI Prime's weekly "Trending" tech newsletter in your email inbox.
Read by 32% of LPs April 29, 2020

Frazier Healthcare Partners Adds Experienced Capital Markets Executive To Life Sciences Team

MENLO PARK, Calif., April 28, 2020-- Frazier Healthcare Partners announced David Topper has joined the Life Sciences team as a Senior Advisor. He has over 35 years of experience in the capital markets. Mr. Topper was formerly the global head of capital markets at a major growth equity investment firm. Prior to that, he was Co-Head of Equity Capital Markets at J.P. Morgan, where he led the firm's major advisory and capital-raising transactions and worked with the U.S. Treasury and other regulatory agencies on crisis-related issues. He also served as Chairman of the Commitments Committee at J.P. Morgan.
Read by 31% of LPs April 23, 2020

Xconomy: Life Science A Vc Bright Spot In Q1, But Startups May Soon Struggle

Even as the novel coronavirus has derailed daily life and business operations, the life sciences sector continues to see companies make public debuts and ink both financing and partnership deals. In venture capital, US deal activity in the first quarter tallied 2,300 financings totaling $34.2 billion, according to the latest report by the National Venture [...]
Read by 71% of LPs